Sure, I'd be happy to. There are two companies that are seeking licensure for their pathogen inactivation technologies in Canada. One of them is the first company that got into the business, and it has been selling products for treatment in blood mostly in Europe initially, but globally at this point. They have enough experience with their technology that they could put a request before Health Canada for approval to market in this country with the experience base they had previously.
The other company is the second one in that came to marketing approvals in Europe about seven years after the first company, so it has less experience. In discussions with Health Canada, this second company was asked to acquire additional clinical experience. Canadian Blood Services has been involved with that company by assisting in doing a clinical trial for the treatment of platelet products with these pathogen inactivation technologies, and we have a trial running in several hospitals in Ontario that should be completed in May.
We do anticipate that marketing approvals will be granted to these two companies some time within the next 24 months, and then we'll have the opportunity to look at implementation in Canada.